News

Find News

Filter articles

Applied Filters

Showing 41 to 50 of 1026 results

GSK responds to Teva’s ‘skinny’ label rehearing petition

US09-12-2021Alex Baldwin

Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.

Teva loses appeal to invalidate Korlym patent

US09-12-2021Alex Baldwin

Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid.

Mylan gets Fed Circ reprieve in inhaler dispute

US09-12-2021Muireann Bolger

Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Galderma sues Lupin over Oracea generic

US07-12-2021Alex Baldwin

Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

02-12-2021

The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact. 

Court denies Sun Pharma’s bid to avoid trial

India, US25-11-2021

Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

Bayer, Onyx drop Nexavar patent suit

US23-11-2021Muireann Bolger

Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.

PTAB grants IPR of Regeneron Eylea patents

US11-11-2021Alex Baldwin

The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

EPO upholds Bayer's Xarelto dosage patents

EU04-11-2021Alex Baldwin

Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.

Pfizer fights approval of generic Ibrance

US21-10-2021

Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.

Showing 41 to 50 of 1026 results

LSIPR